Sex, gender, and pharmaceutical politics: From drug development to marketing

Gender Medicine

Volumn 7, Issue 4, 2010, Pages 357-370

  Fisher, Jill A ^a   Ronald, Lorna M ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

direct to consumer advertising; drug development; HPV quadrivalent vaccine; marketing; mifepristone; pharmaceutical regulation; Phase I trials; sildenafil citrate; tegaserod

Indexed keywords

MIFEPRISTONE; SILDENAFIL; TEGASEROD; WART VIRUS VACCINE;

CANADA; DRUG APPROVAL; DRUG CONTROL; DRUG INDUSTRY; DRUG MARKETING; ERECTILE DYSFUNCTION; ETHNICITY; EUROPE; FEMALE; FOOD AND DRUG ADMINISTRATION; GENDER; HUMAN; IRRITABLE COLON; JAPAN; MALE; NOTE; POLICY; POLITICS; PRESCRIPTION; PRIORITY JOURNAL; SEX; SEX DIFFERENCE; SEX ROLE; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; VERRUCA VULGARIS;

ADVERTISING AS TOPIC; CANADA; CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; EUROPE; FEMALE; GENDER IDENTITY; HUMANS; JAPAN; LEGISLATION, DRUG; MARKETING; POLITICS; PRODUCT SURVEILLANCE, POSTMARKETING; SEX CHARACTERISTICS; UNITED STATES;

EID: 77957350260     PISSN: 15508579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genm.2010.08.003     Document Type: Note

References (76)

1. L Bren Does sex make a difference? FDA Consum Mag 39 2005 10 15
2. A Khan, AE Brodhead, and KA Schwartz Sex differences in antidepressant response in recent antidepressant clinical trials J Clin Psychopharmacol 25 2005 318 324
3. US Government Accountability Office (GAO) Drug safety: Most drugs withdrawn in recent years had greater health risks for women. Washington, DC; 2001. Report no. GAO-01-286R http://www.gao.gov/new.items/d01286r.pdf Accessed July 12, 2010
4. J Arney, and A Rafalovich Incomplete syllogisms as techniques of medicalization: The case of direct-to-consumer advertising in popular magazines, 1997 to 2003 Qual Health Res 17 2007 49 60
5. RA Chananie Psychopharmaceutical advertising strategies: Empowerment in a pill? Sociol Spectr 25 2005 487 518
6. DL Frosch, PM Krueger, and RC Hornik Creating demand for prescription drugs: A content analysis of television direct-to-consumer advertising [published correction appears in Ann Fam Med. 2007; 5:179] Ann Fam Med 5 2007 6 13
7. US Government Accountability Office (GAO) Prescription drugs: FDA oversight of direct-to-consumer advertising has limitations. Washington, DC; 2002. Report no. GAO-03-177 http://www.gao.gov/new.items/d03177.pdf Accessed July 12, 2010
8. JM Grow, JS Park, and X Han "Your life is waiting!" Symbolic meanings in direct-to-consumer antidepressant advertising J Commun Inq 30 2006 163 188
9. A Kallen, S Woloshin, and J Shu Direct-to-consumer advertisements for HIV antiretroviral medications: A progress report Health Aff (Millwood) 26 2007 1392 1398
10. KA Kaphingst, W DeJong, RE Rudd, and LH Daltroy A content analysis of direct-to-consumer television prescription drug advertisements J Health Commun 9 2004 515 528
11. J Kempner Gendering the migraine market: Do representations of illness matter? Soc Sci Med 63 2006 1986 1997
12. JD Klausner, A Kim, and C Kent Are HIV drug advertisements contributing to increases in risk behavior among men in San Francisco, 2001? AIDS 16 2002 2349 2350
13. M Wakefield, and R Durrant Effects of exposure of youths at risk for smoking to television advertising for nicotine replacement therapy and Zyban: An experimental study Health Commun 19 2006 253 258 (Pubitemid 43989064)
14. C Wienke Male sexuality, medicalization, and the marketing of Cialis and Levitra Sex Culture 9 2005 29 57
15. S Woloshin, LM Schwartz, J Tremmel, and HG Welch Direct-to-consumer advertisements for prescription drugs: What are Americans being sold? Lancet 358 2001 1141 1146
16. L Mamo, and JR Fosket Scripting the body: Pharmaceuticals and the (re)making of menstruation Signs: J Women Culture Soc 34 2009 925 949
17. D Josefson FDA warning to manufacturers of AIDS drugs BMJ 322 2001 1143
18. Eli Lilly and Company Straight talk. 2000 Annual report http://files.shareholder.com/downloads/LLY/0x0x221674/F5DC5925-4850-4202-A324- A0F0607EC57C/(%3Cem%3Efinancials%20not%20included%3C/em%3E).pdf Accessed February 12, 2010
19. N Greenslit Depression and consumption: Psychopharmaceuticals, branding, and new identity practices Cult Med Psychiatry 29 2005 477 502
20. D Herzberg Happy Pills in America: From Miltown to Prozac 2009 The Johns Hopkins University Press Baltimore, Md
21. US Food and Drug Administration Letter to Eli Lilly and Company, November 16, 2000. Re: NDA #28-936, Sarafem (fluoxetine HCl) Tablets, MACMIS #9523 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/ EnforcementActivitiesbyFDAWarningLettersandNoticeofViolationLetterstoPharmaceu ticalCompanies/UCM166304.pdf Accessed July 12, 2010
22. PJ Hilts Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation 2003 Alfred A. Knopf New York, NY
23. M Angell The Truth About the Drug Companies: How They Deceive Us and What to Do About It 2004 Random House New York, NY
24. J Donohue A History of drug advertising: The evolving roles of consumers and consumer protection Milbank Q 84 2006 659 699
25. L Ronald Empowered to Consume: Direct-to-Consumer Advertising and Pharmaceutical Governance 2006 Rensselaer Polytechnic Institute Troy, NY [dissertation]
26. J Biddle Lessons from the Vioxx debacle: What the privatization of science can teach us about social epistemology Soc Epistemol 21 2007 21 39
27. J La Puma, and J Seltzer Phase IV market steams ahead CenterWatch 9 2002 9 13
28. J Lexchin Lifestyle drugs: Issues for debate CMAJ 164 2001 1449 1451
29. ME Wiktorowicz Emergent patterns in the regulation of pharmaceuticals: Institutions and interests in the United States, Canada, Britain, and France J Health Polit Policy Law 28 2003 615 658
30. Pharmaceuticals and Medical Devices Agency, Japan (PMDA) History http://www.pmda.go.jp/english/about/history.html Accessed July 13, 2009
31. J Kahn Harmonizing race: Competing regulatory paradigms of racial categorization in international drug development Santa Clara J Int Law 5 2006 34 56
32. MJ Nuijten, P Berto, and G Berdeaux Trends in decision-making process for pharmaceuticals in Western European countries HEPAC Health Econ Prev 2 2001 162 169
33. S Epstein Inclusion: The Politics of Difference in Medical Research 2007 University of Chicago Press Chicago, Ill
34. US Government Accountability Office (GAO) Women's health: Women sufficiently represented in new drug testing, but FDA oversight needs improvement. Washington, DC; 2001. Report no. GAO-01-754 http://www.gao.gov/new. items/d01754.pdf Accessed July 12, 2010
35. D Carpenter Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA 2010 Princeton University Press Princeton, NJ
36. I Hollander Viagra's rise above women's health issues: An analysis of the social and political influences on drug approvals in the United States and Japan Soc Sci Med 62 2006 683 693
37. L Noah A miscarriage in the drug approval process? Mifepristone embroils the FDA in abortion politics Wake Forest L Rev 36 2001 571 603
38. US Government Accountability Office (GAO) US Food and Drug Administration: Approval and oversight of the drug Mifeprex. Washington, DC; 2008. Report no. GAO-08-751 http://www.gao.gov/new.items/d08751.pdf Accessed July 12, 2010
39. RA Kloner, and RM Zusman Cardiovascular effects of sildenafil citrate and recommendations for its use Am J Cardiol 84 1999 11N 17N
40. BL Marshall 'Hard science': Gendered constructions of sexual dysfunction in the 'Viagra age' Sexualities 5 2002 131 158
41. E Pinnow, P Sharma, and A Parekh Increasing participation of women in early phase clinical trials approved by the FDA Womens Health Issues 19 2009 89 93
42. OP Corrigan "First in man": The politics and ethics of women in clinical drug trials Fem Rev. 72 2002 40 52
43. L Birke In pursuit of difference: Scientific studies of women and men M Lederman, I Bartsch, The Gender and Science Reader. London, UK 2001 Routledge New York, NY 309 322
44. JA Fisher Medical Research for Hire: The Political Economy of Pharmaceutical Clinical Trials 2009 Rutgers University Press New Brunswick, NJ
45. OP Corrigan A risky business: The detection of adverse drug reactions in clinical trials and post-marketing exercises Soc Sci Med. 55 2002 497 507
46. MA Miller Gender-based differences in the toxicity of pharmaceuticalsThe Food and Drug Administration's perspective Int J Toxicol. 20 2001 149 152
47. M Rademaker Do women have more adverse drug reactions? Am J Clin Dermatol 2 2001 349 351
48. B Meibohm, I Beierle, and H Derendorf How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41 2002 329 342
49. RM Martin, PN Biswas, and SN Freemantle Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: Analysis of 48 cohort studies Br J Clin Pharmacol 46 1998 505 511
50. JB Schwartz The current state of knowledge on age, sex, and their interactions on clinical pharmacology Clin Pharmacol Ther. 82 2007 87 96
51. A Lippman Human papillomavirus (HPV) vaccination and the development of public policies J Epidemiol Community Health 62 2008 570 571
52. DM Parkin The global health burden of infection-associated cancers in the year 2002 Int J Cancer 118 2006 3030 3044
53. H zur Hausen Papillomaviruses in human genital cancer Med Oncol Tumor Pharmacother 4 1987 187 192
54. JM Palefsky, EA Holly, and CJ Hogeboom Anal cytology as a screening tool for anal squamous intraepithelial lesions J Acquir Immune Defic Syndr Hum Retrovirol 14 1997 415 422
55. MJ Casper, and LM Carpenter Sex, drugs, and politics: The HPV vaccine for cervical cancer Sociol Health Illn 30 2008 886 899
56. US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER) Vaccines and Related Biological Products Advisory Committee Meeting. Gaithersburg, Md: 2006 http://www.fda.gov/ohrms/dockets/ac/06/ transcripts/2006-4333t1.pdf Accessed July 12, 2010
57. AR Giuliano, and D Salmon The case for a genderneutral (universal) human papillomavirus vaccination policy in the United States: Point Cancer Epidemiol Biomarkers Prev. 17 2008 805 808
58. JA Fisher, and L Ronald Direct-to-consumer responsibility: Medical neoliberalism in pharmaceutical advertising and drug development SM Chambr, M Goldner, Patients, Consumers and Civil Society (Advances in Medical Sociology) 10th ed. 2008 Emerald Publishing Brighton, UK 29 51
59. L Chang, and MM Heitkemper Gender differences in irritable bowel syndrome Gastroenterology 123 2002 1686 1701
60. M Heitkemper, M Jarrett, EF Bond, and L Chang Impact of sex and gender on irritable bowel syndrome Biol Res Nurs. 5 2003 56 65
61. LA Houghton, R Lea, N Jackson, and PJ Whorwell The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers Gut. 50 2002 471 474
62. SL Lucak, and MM Heitkemper The experts discuss irritable bowel syndrome J Womens Health Gend Based Med. 10 2001 223 228
63. JC Wootton Irritable bowel syndrome J Womens Health Gend Based Med. 9 2000 803 805
64. KA Gwee Irritable bowel syndrome in developing countriesa disorder of civilization or colonization? Neurogastroenterol Motil. 17 2005 317 324
65. BB Toner, and D Akman Gender role and irritable bowel syndrome: Literature review and hypothesis Am J Gastroenterol 95 2000 11 16
66. RE Williams, CL Black, and HY Kim Determinants of healthcare-seeking behaviour among subjects with irritable bowel syndrome Aliment Pharmacol Ther. 23 2006 1667 1675
67. S Payne Sex, gender, and irritable bowel syndrome: Making the connections Gend Med. 1 2004 18 28
68. US Food and Drug Administration Gastrointestinal Drugs Advisory Committee, November 16, 1999 http://www.fda.gov/ohrms/dockets/ac/99/transcpt/ 3565t1a.pdf Accessed July 12, 2010
69. R Horton Lotronex and the FDA: A fatal erosion of integrity Lancet 357 2001 1544 1545
70. US Food and Drug Administration Gastrointestinal Drugs Advisory Subcommittee Meeting July 14 2004 http://www.fda.gov/ohrms/dockets/ac/04/ transcripts/2004-4056T1.pdf Accessed July 12, 2010
71. R Lea, and PJ Whorwell Benefit-risk assessment of tegaserod in irritable bowel syndrome Drug Saf. 27 2004 229 242 (Pubitemid 38372903)
72. US Food and Drug Administration Letter to Novartis, June 27, 2003 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ EnforcementActivitiesbyFDA/ WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM168920. pdf Accessed July 12, 2010
73. SD Dorn, JF Farley, and RA Hansen Direct-to-consumer and physician promotion of tegaserod correlated with physician visits, diagnoses, and prescriptions Gastroenterology 137 2009 518 524
74. SD Dorn, JF Farley, and RA Hansen Direct-to-consumer and physician promotion of tegaserod correlated with physician visits, diagnoses, and prescriptions Gastroenterology 137 2009 524.e1 524.e2
75. LR Schiller, and DA Johnson Balancing drug risk and benefit: Toward refining the process of FDA decisions affecting patient care Am J Gastroenterol 103 2008 815 819
76. LM Blum, and NF Stracuzzi Gender in the Prozac nation: Popular discourse and productive femininity Gend Soc. 18 2004 269 286